NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma (Q85068204)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

Sally Doss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Nicola Hay

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Frances Sutcliffe

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

1 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

837-838

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970202-9

7 January 2021

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970202-9

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970202-9

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970202-9

7 January 2021

10.1016/S1470-2045(11)70202-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21984992%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference